ArticleDysphagia2026
Dysphagia in Older Adults with Malignant Brain Tumors: Results of a National Study of Medicare Beneficiaries.
Article in Dysphagia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The risk of swallowing dysfunction increases with age and is associated with underlying neurological conditions. However, the prevalence of dysphagia and its impact on outcomes among older adults with brain tumors is unknown. We aimed to determine the prevalence of dysphagia among patients ≥ 65 years with brain tumors and evaluate the relationship between dysphagia and outcomes, including healthcare utilization and survival, within this group. We hypothesized that the rates of dysphagia would be higher among those with brain cancer compared to those with solid organ cancer, and that nutrition via enteral access would not improve survival. Using a Medicare 5% limited dataset (2013-2018), we identified beneficiaries (≥ 65 years) with malignant brain tumors and measured the prevalence of dysphagia by ICD-9/10 codes. We compared outcomes and rates of dysphagia-related care among beneficiaries with primary malignant brain tumors (PMBTs) and those with solid tumors (with and without brain metastases) using current procedural terminology (CPT) codes. Beneficiaries with coexisting disorders predisposing to dysphagia were excluded. Kaplan Meier curves were used to estimate survival. Dysphagia was more prevalent among beneficiaries with PMBTs (11.0%) compared to those with solid tumors with (7.9%) and without (4.4%) brain metastases (p < 0.01). The presence of dysphagia was significantly associated with hospitalization (p < 0.01), use of gastrointestinal (GI) services (p < 0.01) and decreased survival: 75% of those with dysphagia survived 319 days post-cancer diagnosis (95% CI: 301, 332), versus 1082 days post-cancer diagnosis for those without dysphagia (95% CI: 1064, 1104) (p < 0.001). Among those with PMBTs, enteral access was not associated with an improvement in survival (p = 0.08). Dysphagia is prevalent among older adults with brain tumors (primary and metastatic) and is associated with increased mortality risk. Enteral access placement among those with PMBTs and dysphagia did not demonstrate improvement in survival.
Indexed as
Identifiers
42277296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.